Coherus, Junshi announce final OS results of JUPITER-02 Phase 3 trial

Shanghai Junshi Biosciences (SHJBF) and Coherus BioSciences (CHRS) today announced results of a final analysis of overall survival from the pivotal study JUPITER-02, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. This final analysis demonstrated a statistically significant and clinically meaningful improvement in OS in NPC patients treated with toripalimab plus chemotherapy compared to chemotherapy alone. These data are being submitted for presentation at an upcoming medical meeting. "In the pivotal JUPITER-02 trial, toripalimab has demonstrated a statistically significant and clinically meaningful overall survival benefit for patients with advanced NPC, an aggressive head and neck tumor with no current FDA-approved treatment options," said Rosh Dias, M.D., Coherus’ CMO. "These mature overall survival data continue to demonstrate the benefit of toripalimab in the treatment of NPC patients, further building upon the data published in Nature Medicine and presented at the 2021 plenary session at the ASCO annual meeting, and clearly show that toripalimab has the potential to become the new standard-of-care for NPC patients, once approved. We look forward to sharing these data with the oncology community at an upcoming medical meeting."